FDA's Bold Move Boosts Biosimilars, US-China Tensions Over Fentanyl, Artificial Cornea Innovation

Today's health news spotlight includes the FDA's proposal to streamline biosimilar drug testing to reduce costs, heightened US-China disagreements over fentanyl at the UN, and noteworthy advancements by Spanish researchers in developing a cost-effective artificial cornea. These developments highlight ongoing global health challenges and innovations.

In an effort to make complex biologic medicines more affordable, the FDA proposed easing rules for biosimilar drug testing. This initiative targets high-cost treatments for cancer and autoimmune diseases, currently dominating over half of the market's drug spending, despite comprising just 5% of prescriptions.

At a United Nations meeting, the United States and China engaged in a heated exchange, with accusations from Washington that Beijing is lax on controlling fentanyl precursor sales. China refuted the claims, intensifying tensions ahead of a planned diplomatic meeting at the month's end.

Spanish researchers have pioneered an innovative artificial cornea using fish scales, offering a lower-cost substitute for traditional donor transplants used to treat severe eye diseases. The scarcity of donor corneas makes this breakthrough particularly significant in addressing the pressing demand.

(With inputs from agencies.)